You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

anti-angiogenic therapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Predict Efficacy of Anti-angiogenic Therapy in Ovarian Cancer

Active, not recruiting
  • Epithelial Ovarian Cancer
  • liquid biopsy
  • Aviano, Italy
    Centro di Riferimento Oncologico (CRO), IRCCS
May 16, 2023

Brain Tumors by Advanced MRI

Completed
  • Glioblastoma
  • Avastin
  • +5 more
  • Boston, Massachusetts
    Massachusetts general Hospital
Apr 6, 2022

Metastatic Renal Cell Carcinoma Trial in Cleveland (Nivolumab, Ipilimumab)

Active, not recruiting
  • Metastatic Renal Cell Carcinoma
  • Cleveland, Ohio
    Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
Jan 25, 2023

Ocular Blood Flow in Colorectal Cancer Patients

Terminated
  • Metastatic Colorectal Cancer
    • Vienna, Austria
      Medical University of Vienna
    Apr 23, 2022

    Hereditary Hemorrhagic Telangiectasia Trial in Toronto (Topical timolol maleate, saline drops)

    Completed
    • Hereditary Hemorrhagic Telangiectasia
    • Topical timolol maleate
    • placebo saline drops
    • Toronto, Ontario, Canada
      St. Michael's Hospital
    Nov 19, 2021

    18F-fluorodeoxyglucose Positron Emission Tomography and Brain

    Recruiting
    • Glioblastoma
    • FDG PET
    • +2 more
    • Nîmes, France
      CHU de Nimes
    Oct 15, 2021

    Glioma, Neuroectodermal Tumors, Primitive, Wilms Tumor Trial in Saint Louis (Metronomic Cyclophosphamide, Thalidomide)

    Recruiting
    • Glioma
    • +6 more
    • Saint Louis, Missouri
      Washington University School of Medicine
    Sep 22, 2021

    Colorectal Cancer Trial in Dijon (OCT- Angiographie)

    Recruiting
    • Colorectal Cancer
    • OCT- Angiographie
    • Dijon, France
    • +1 more
    Jul 2, 2021

    NSCLC Trial in Changsha (envafolimab)

    Enrolling by invitation
    • Non-small Cell Lung Cancer
    • Changsha, Hunan, China
      the second Xiangya hospital
    May 1, 2022

    Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC

    Recruiting
    • Hepatocellular Carcinoma
    • Anti-angiogenic agents plus anti-PD-1/PD-L1 antibodies
    • Shanghai, Shanghai, China
      Zhongshan Hospital, Fudan University
    Jul 23, 2021

    Rare Tumor, Refractory Tumor Trial in Shanghai (Gefitinib, Erlotinib, Afatinib)

    Recruiting
    • Rare Tumor
    • Refractory Tumor
    • Shanghai, Shanghai, China
      Shanghai Changzheng Hospital
    Feb 16, 2022

    Colon Cancer With Metastases to the Liver Trial in Argentina, United States (LC beads loaded with Irinotecan, Oxaliplatin,

    Completed
    Has Results
    • Colon Cancer With Metastases to the Liver
    • LC beads loaded with Irinotecan
    • +4 more
    • Huntsville, Alabama
    • +9 more
    Jun 9, 2021

    Solid Tumor, Adult, Solid Tumor, Gastric Cancer Trial in Seongnam, Seoul (PB101)

    Recruiting
    • Solid Tumor, Adult
    • +5 more
    • Seongnam, Korea, Republic of
    • +2 more
    Oct 11, 2023

    Collateral Damage From COVID-19 Pandemic Observed in Patients

    Completed
    • Age Related Macular Degeneration
    • +2 more
    • Questionnaire
    • Data collection up to 1 year
    • Ecully, France
    • +3 more
    Mar 2, 2022

    SNP-polymorphisms in Post-infarction Cardiac Remodeling

    Completed
    • Myocardial Infarction
    • SNP polymorphisms of the promoter regions pro - and anti-inflammatory cytokines and angiogenic growth factor
    • Tomsk, Tomskii Region, Russian Federation
      Cardiology Research Institute of Tomsk National Research Medical
    Oct 5, 2021

    Metastatic Renal Cell Carcinoma Trial in France (Nivolumab)

    Completed
    • Metastatic Renal Cell Carcinoma
    • Caen, France
    • +6 more
    Oct 5, 2021

    Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for

    Recruiting
    • Hepatocellular Carcinoma Non-resectable
    • TACE
    • +8 more
    • Quanzhou, Fujian, China
    • +3 more
    Jan 29, 2023

    Surufatinib Plus Sintilimab Combined With Chemotherapy in

    Recruiting
    • Gastric Neuroendocrine Carcinoma
    • Tianjin, Tianjin, China
      Tianjin Medical University Cancer Institute and Hospital
    Oct 22, 2023

    Anti-Angiogenic Preeclampsia Milieu Impairs Infant Lung and

    Completed
    • Preeclampsia
    • Diffusion Lung Capacity (DLCO), Vascular Challenge, Video Imaging, Specimen Collections
    • Indianapolis, Indiana
      Riley Hospital for Children
    Feb 22, 2022

    Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy Trial in Guangzhou (Toripalimab,

    Not yet recruiting
    • Muscle-Invasive Bladder Carcinoma
    • +2 more
    • Guangzhou, Guangdong, China
      Cancer Center, Sun Yat-sen University
    Aug 3, 2023

    Therapy of Anti-NMDAR Encephalitis at Diagnosis

    Active, not recruiting
    • Anti-NMDA (N-Methyl D-Aspartate) Receptor Encephalitis
      • Rotterdam, Netherlands
        Erasmus Medical Center
      Sep 4, 2023

      Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti Tim-3/CD123 CAR-T cell therapy)

      Recruiting
      • Acute Myeloid Leukemia Refractory
      • Acute Myeloid Leukemia, in Relapse
      • anti Tim-3/CD123 CAR-T cell therapy
      • Xuzhou, Jiangsu, China
        Kailin Xu
      Nov 4, 2023

      Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1 Trial in Shanghai (Camrelizumab (anti-PD-1 inhibitor), Apatinib

      Recruiting
      • Oral Squamous Cell Carcinoma
      • +3 more
      • Camrelizumab (anti-PD-1 inhibitor)
      • Apatinib (anti-VEGFR inhibitor)
      • Shanghai, Shanghai, China
        Ninth People's Hospital, Shanghai Jiao Tong University School of
      Oct 8, 2022

      Osteonecrosis Due to Drugs, Jaw Trial in Besançon (Human Amniotic Membrane, Conventional/Standard treatment)

      Active, not recruiting
      • Osteonecrosis Due to Drugs, Jaw
      • Human Amniotic Membrane
      • Conventional/Standard treatment
      • Besançon, France
        CHU de Besancon
      Dec 21, 2022

      Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto

      Not yet recruiting
      • Multiple Sclerosis
      • +2 more
      • KYV-101 anti-CD19 CAR-T cell therapy
      • Standard lymphodepletion regimen
      • Palo Alto, California
        Stanford Multiple Sclerosis Center
      Nov 13, 2023